

# Ignacio PÃ©rez-Valero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4065868/publications.pdf>

Version: 2024-02-01

72  
papers

2,360  
citations

236925  
25  
h-index

214800  
47  
g-index

77  
all docs

77  
docs citations

77  
times ranked

3154  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Sjögren Syndrome in Spain. <i>Medicine (United States)</i> , 2008, 87, 210-219.	1.0	459
2	Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. <i>Journal of the American Heart Association</i> , 2014, 3, e000844.	3.7	184
3	Dual treatment with lopinavir/ritonavir plus lamivudine versus triple treatment with lopinavir/ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 785-792.	9.1	131
4	Dual treatment with atazanavir/ritonavir plus lamivudine versus triple treatment with atazanavir/ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 775-784.	9.1	122
5	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. <i>Clinical Infectious Diseases</i> , 2017, 65, 2112-2118.	5.8	88
6	Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study. <i>AIDS Patient Care and STDs</i> , 2018, 32, 112-118.	2.5	84
7	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV, the</i> , 2018, 5, e23-e34.	4.7	83
8	Protease inhibitor monotherapy and the CNS: peace of mind?. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1954-1962.	3.0	56
9	Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1000-1006.	1.1	56
10	Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1359-1361.	3.0	52
11	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. <i>Aids</i> , 2019, 33, 475-481.	2.2	44
12	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. <i>Antiviral Therapy</i> , 2012, 17, 1-8.	1.0	43
13	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV, the</i> , 2017, 4, e205-e213.	4.7	43
14	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naïve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. <i>Journal of Clinical Microbiology</i> , 2012, 50, 407-413.	3.9	41
15	Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. <i>HIV Medicine</i> , 2013, 14, 273-283.	2.2	39
16	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw059.	0.9	34
17	Cardiac valve replacement in patients with antiphospholipid syndrome. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	3.4	32
18	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. <i>Antiviral Research</i> , 2019, 170, 104543.	4.1	32

#	ARTICLE	IF	CITATIONS
19	Protease inhibitor monotherapy. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 7-11.	3.1	31
20	Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. <i>HIV Medicine</i> , 2014, 15, 213-223.	2.2	30
21	Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. <i>Aids</i> , 2017, 31, 1253-1260.	2.2	30
22	Switching regimens in virologically suppressed HIV-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. <i>HIV Medicine</i> , 2016, 17, 3-16.	2.2	29
23	Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2018, 67, 770-777.	5.8	29
24	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. <i>Aids</i> , 2012, 26, 1829-1834.	2.2	27
25	Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class. <i>Clinical Microbiology and Infection</i> , 2012, 18, E485-E490.	6.0	26
26	Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2010, 17, 714-719.	2.0	23
27	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1-Infected Patients Treated With Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 21-29.	2.1	23
28	Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-1-Infected Adults. <i>Journal of Infectious Diseases</i> , 2018, 218, 1531-1540.	4.0	22
29	Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e69493.	2.5	22
30	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS). <i>Antiviral Research</i> , 2011, 89, 19-25.	4.1	20
31	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004–2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	2.5	19
32	A Prospective Cohort Study of Neurocognitive Function in Aviremic HIV-Infected Patients Treated With 1 or 3 Antiretrovirals. <i>Clinical Infectious Diseases</i> , 2014, 59, 1627-1634.	5.8	19
33	Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 102-109.	2.1	19
34	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010. <i>BMC Infectious Diseases</i> , 2013, 13, 382.	2.9	18
35	Idiopathic intracranial hypertension and systemic lupus erythematosus: a case report and review of the literature. <i>Lupus</i> , 2009, 18, 1121-1123.	1.6	17
36	Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations. <i>PLoS ONE</i> , 2014, 9, e90710.	2.5	17

#	ARTICLE	IF	CITATIONS
37	Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients. <i>Aids</i> , 2016, 30, 75-82.	2.2	16
38	Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. <i>HIV Medicine</i> , 2010, 11, 439-447.	2.2	15
39	Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008-2010. <i>Antiviral Therapy</i> , 2013, 18, 161-170.	1.0	14
40	Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort. <i>HIV Medicine</i> , 2014, 15, 86-97.	2.2	12
41	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 700-708.	1.2	11
42	Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2014, 14, 379.	2.9	11
43	Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases. <i>Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ­nica</i> , 2011, 29, 263-268.	0.5	9
44	Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. <i>Journal of NeuroVirology</i> , 2014, 20, 362-370.	2.1	8
45	Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	8
46	Letter to the Editor. <i>Lupus</i> , 2005, 14, 979-980.	1.6	7
47	Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19578.	3.0	7
48	Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 91-94.	2.1	7
49	Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy. <i>AIDS Reviews</i> , 2014, 16, 101-8.	1.0	7
50	Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat. <i>AIDS Reviews</i> , 2015, 17, 114-20.	1.0	7
51	Boosted Lopinavir Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	5.8	6
52	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2444-2451.	3.0	6
53	Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 466-472.	3.0	6
54	Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 490-495.	2.1	6

#	ARTICLE	IF	CITATIONS
55	A Comparative Study of Neurocognitively Impaired Patients Receiving Protease Inhibitor Monotherapy or Triple-Drug Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 419-423.	2.1	5
56	Ictus and antiphospholipid syndrome: How much is enough?. <i>Autoimmunity</i> , 2008, 41, 140-142.	2.6	4
57	CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19656.	3.0	4
58	Facial Emotion Processing in Aviremic HIV-infected Adults. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 401-410.	0.5	4
59	Facial emotional processing deficits in long-term HIV-suppressed patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19664.	3.0	3
60	Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIV. <i>HIV Medicine</i> , 2022, 23, 969-977.	2.2	3
61	Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?. <i>Aids</i> , 2013, 27, 141-144.	2.2	2
62	Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance. <i>Aids</i> , 2014, 28, 932-934.	2.2	2
63	Vocal emotion processing deficits in HIV-infected individuals. <i>Journal of NeuroVirology</i> , 2017, 23, 304-312.	2.1	2
64	Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa482.	0.9	2
65	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. <i>Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ­nica</i> , 2022, 40, 121-124.	0.5	2
66	Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw041.	0.9	1
67	Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy. <i>Aids</i> , 2010, 24, 2415-2316.	2.2	0
68	Comments to Garvey et al.: "Low Rates of Neurocognitive Impairment Are Observed in Neuro-Asymptomatic HIV-Infected Subjects on Effective Antiretroviral Therapy" <i>HIV Clinical Trials</i> , 2012, 13, 296-298.	2.0	0
69	Second-line antiretroviral therapy and the human factor. <i>Lancet HIV</i> , 2015, 2, e34-e35.	4.7	0
70	Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. <i>Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ­nica</i> , 2016, 34, 29-32.	0.5	0
71	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	2.2	0
72	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, 40, 121-124.	0.3	0